Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug Administration approved the company's non-opioid pain treatment.

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

The Japanese conglomerate is in talks to spend up to $43 billion to boost the ChatGPT developer. Novartis expects profit and sales to grow further this year after beating analysts' expectations, ...

Americans Direct proudly announces its official launch, offering a groundbreaking platform that connects businesses, causes, and crowdfunding initiatives with a highly engaged and active pro-American ...

American Hotel Income Properties REIT LP ("AHIP") , today announced the completion of a commercial mortgage-backed securities ("CMBS") refinancing for five hotel properties with total gross proceeds ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...

The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...